03/11/2024 6:19 PM | Chemomab Therapeutics (Subject) OrbiMed Israel BioFund GP Limited Partnership (Filed by)
| Form SC 13D/A | |
03/07/2024 6:00 AM | Chemomab Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/03/2024 6:00 AM | Chemomab Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/15/2023 3:35 PM | Chemomab Therapeutics (Subject) OrbiMed Israel BioFund GP Limited Partnership (Filed by)
| Form SC 13D/A | |
11/09/2023 7:00 AM | Chemomab Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/05/2023 11:15 PM | Chemomab Therapeutics (Filer)
| Form EFFECT | |
10/30/2023 7:33 AM | Chemomab Therapeutics (Filer)
| Form F-3/A | |
10/16/2023 3:25 PM | Chemomab Therapeutics (Filer)
| Form F-3 Registration statement for securities of certain foreign private issuers | |
08/14/2023 7:05 AM | Chemomab Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/08/2023 5:00 AM | Chemomab Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/05/2023 4:48 PM | Chemomab Therapeutics (Issuer) Darvish Nissim (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/03/2023 2:49 PM | Chemomab Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/20/2023 5:03 AM | Chemomab Therapeutics (Issuer) Quigley Jill M. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/05/2023 3:54 PM | Chemomab Therapeutics (Issuer) Fatal Sigal (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
06/05/2023 6:00 AM | Chemomab Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/11/2023 5:07 AM | Chemomab Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/11/2023 5:10 AM | Chemomab Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |